Literature DB >> 35664825

Targeted Cancer Therapy and Its Ophthalmic Side Effects: A Review.

Shruthi Harish Bindiganavile1, Nita Bhat1, Andrew G Lee1,2,3,4,5,6,7, Dan S Gombos4,7, Nagham Al-Zubidi1,2,7.   

Abstract

Targeted cancer therapy agents are the latest development in cancer therapeutics. Although the spectrum of their use continues to expand, ocular side effects are frequently encountered with the use of cancer therapeutics. This review describes the ocular side effects of targeted cancer therapy agents. © Innovative Healthcare Institute.

Entities:  

Keywords:  cancer immunotherapy; immune-related adverse events; ocular side effects

Year:  2021        PMID： 35664825      PMCID： PMC9161666          DOI： 10.36401/JIPO-20-21

Source DB:  PubMed          Journal:  J Immunother Precis Oncol        ISSN： 2590-017X


  105 in total

1.  Posterior subcapsular cataracts and hypotony secondary to severe pembrolizumab induced uveitis: Case report.

Authors:  Alfred Basilious; John C Lloyd
Journal:  Can J Ophthalmol       Date:  2016-02       Impact factor: 1.882

2.  Bilateral macular ischemia and severe visual loss following trastuzumab therapy.

Authors:  Maher Saleh; Tristan Bourcier; Georges Noel; Claude Speeg-Schatz; David Gaucher
Journal:  Acta Oncol       Date:  2011-02-08       Impact factor: 4.089

3.  Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy: Differences from Central Serous Chorioretinopathy.

Authors:  Jasmine H Francis; Larissa A Habib; David H Abramson; Lawrence A Yannuzzi; Murk Heinemann; Mrinal M Gounder; Rachel N Grisham; Michael A Postow; Alexander N Shoushtari; Ping Chi; Neil H Segal; Rona Yaeger; Alan L Ho; Paul B Chapman; Federica Catalanotti
Journal:  Ophthalmology       Date:  2017-07-12       Impact factor: 12.079

4.  Birdshot-like Chorioretinopathy Associated With Pembrolizumab Treatment.

Authors:  Luis A Acaba-Berrocal; J Antonio Lucio-Alvarez; Arman Mashayekhi; Allen C Ho; James P Dunn; Carol L Shields
Journal:  JAMA Ophthalmol       Date:  2018-10-01       Impact factor: 7.389

5.  Tyrosine kinase inhibitors: Multi-targeted or single-targeted?

Authors:  Fleur Broekman; Elisa Giovannetti; Godefridus J Peters
Journal:  World J Clin Oncol       Date:  2011-02-10

Review 6.  Retinal toxicities of cancer therapy drugs: biologics, small molecule inhibitors, and chemotherapies.

Authors:  Catherine Y Liu; Jasmine H Francis; Scott E Brodie; Brian Marr; Jose S Pulido; Michael F Marmor; David H Abramson
Journal:  Retina       Date:  2014-07       Impact factor: 4.256

7.  Optic disc edema as a possible complication of Imatinib mesylate (Gleevec).

Authors:  Soon-Il Kwon; Dae-Hyoung Lee; Yun-Jeong Kim
Journal:  Jpn J Ophthalmol       Date:  2008-09-05       Impact factor: 2.447

8.  Ocular toxicity due to Trametinib and Dabrafenib.

Authors:  Stephanie Sarny; Michael Neumayer; Julian Kofler; Yosuf El-Shabrawi
Journal:  BMC Ophthalmol       Date:  2017-08-17       Impact factor: 2.209

Review 9.  Immuno-Oncology: Emerging Targets and Combination Therapies.

Authors:  Henry T Marshall; Mustafa B A Djamgoz
Journal:  Front Oncol       Date:  2018-08-23       Impact factor: 6.244

10.  Ocular adverse events with immune checkpoint inhibitors.

Authors:  Tony Fang; David A Maberley; Mahyar Etminan
Journal:  J Curr Ophthalmol       Date:  2019-06-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.